Gene: KLHL35
Official Full Name: kelch like family member 35provided by HGNC
Gene Summary: Predicted to enable ubiquitin-like ligase-substrate adaptor activity. Predicted to be involved in proteasome-mediated ubiquitin-dependent protein catabolic process. Predicted to be part of Cul3-RING ubiquitin ligase complex. Predicted to be active in cytoplasm. [provided by Alliance of Genome Resources, Apr 2025]
Catalog Number | Product Name | Species | Gene | Passage ratio | Mycoplasma testing | Price |
---|---|---|---|---|---|---|
KO16652 | KLHL35 Knockout cell line (HeLa) | Human | KLHL35 | 1:3~1:6 | Negative | Online Inquiry |
KO16653 | KLHL35 Knockout cell line (HCT 116) | Human | KLHL35 | 1:2~1:4 | Negative | Online Inquiry |
KO16654 | KLHL35 Knockout cell line (A549) | Human | KLHL35 | 1:3~1:4 | Negative | Online Inquiry |
KLHL35 Gene Knockout Cell Lines are specifically developed cellular models that have been engineered to lack the expression of the KLHL35 gene, an important regulator involved in various biological processes, including protein degradation and cellular signaling. This precise knockout allows researchers to investigate the role of KLHL35 in cellular pathways, assess the implications of its absence, and evaluate potential interactions with other genes.
The key mechanism behind these cell lines involves CRISPR-Cas9 technology, a revolutionary gene-editing tool that enables targeted modifications within the genome. By leveraging this technology, the KLHL35 gene can be effectively disrupted, resulting in robust and reproducible gene knockout models that retain viability and functionality for downstream applications.
The scientific importance of KLHL35 Gene Knockout Cell Lines lies in their applicability within both research and clinical settings. They afford researchers the ability to explore the pathophysiological roles of KLHL35 in diseases such as cancer, neurodegeneration, and autoimmune disorders. The insights gained from these studies can inform the development of novel therapeutic strategies and biomarkers.
Compared to alternative knockout models, KLHL35 Gene Knockout Cell Lines offer several distinct advantages. These include validated gene disruption, a consistent background cell line, and easy adaptability for high-throughput screening. They provide a comprehensive platform for functional genomics and drug discovery, thereby accelerating the pace of research while reducing experimental variability.
For researchers and clinicians alike, the KLHL35 Gene Knockout Cell Lines represent a valuable tool for advancing understanding of gene function and therapeutic development. Backed by our extensive expertise in genetic engineering and cellular biology, our company is committed to delivering high-quality biological products that empower scientific discovery and innovation in the life sciences.
Please note that all services are for research use only. Not intended for any clinical use.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
There is no product in your cart. |
CD Biosynsis is a leading customer-focused biotechnology company dedicated to providing high-quality products, comprehensive service packages, and tailored solutions to support and facilitate the applications of synthetic biology in a wide range of areas.